Akouos, Inc.

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, VRTX has a market cap of 118.3B. Regarding current trading prices, AKUS is priced at $13.29, while VRTX trades at $460.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas VRTX's P/E ratio is -121.27. In terms of profitability, AKUS's ROE is -0.32%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, AKUS is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check VRTX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, REGN has a market cap of 59.3B. Regarding current trading prices, AKUS is priced at $13.29, while REGN trades at $558.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas REGN's P/E ratio is 14.19. In terms of profitability, AKUS's ROE is -0.32%, compared to REGN's ROE of +0.15%. Regarding short-term risk, AKUS is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check REGN's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, AKUS is priced at $13.29, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas SGEN's P/E ratio is -57.19. In terms of profitability, AKUS's ROE is -0.32%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, AKUS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check SGEN's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ALNY has a market cap of 42.4B. Regarding current trading prices, AKUS is priced at $13.29, while ALNY trades at $324.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ALNY's P/E ratio is -154.67. In terms of profitability, AKUS's ROE is -0.32%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, AKUS is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check ALNY's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ARGX has a market cap of 36.4B. Regarding current trading prices, AKUS is priced at $13.29, while ARGX trades at $595.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ARGX's P/E ratio is 36.29. In terms of profitability, AKUS's ROE is -0.32%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, AKUS is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check ARGX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, BNTX has a market cap of 27.1B. Regarding current trading prices, AKUS is priced at $13.29, while BNTX trades at $112.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas BNTX's P/E ratio is -30.03. In terms of profitability, AKUS's ROE is -0.32%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, AKUS is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check BNTX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, RPRX has a market cap of 20.8B. Regarding current trading prices, AKUS is priced at $13.29, while RPRX trades at $37.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas RPRX's P/E ratio is 15.13. In terms of profitability, AKUS's ROE is -0.32%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, AKUS is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check RPRX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, SMMT has a market cap of 20.4B. Regarding current trading prices, AKUS is priced at $13.29, while SMMT trades at $27.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas SMMT's P/E ratio is -80.74. In terms of profitability, AKUS's ROE is -0.32%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, AKUS is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check SMMT's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, AKUS is priced at $13.29, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas BGNE's P/E ratio is -22.55. In terms of profitability, AKUS's ROE is -0.32%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, AKUS is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check BGNE's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, AKUS is priced at $13.29, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, AKUS's ROE is -0.32%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, AKUS is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check DNA-WT's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, GMAB has a market cap of 14.2B. Regarding current trading prices, AKUS is priced at $13.29, while GMAB trades at $23.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas GMAB's P/E ratio is 13.58. In terms of profitability, AKUS's ROE is -0.32%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, AKUS is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check GMAB's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, INCY has a market cap of 13.6B. Regarding current trading prices, AKUS is priced at $13.29, while INCY trades at $70.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas INCY's P/E ratio is 350.80. In terms of profitability, AKUS's ROE is -0.32%, compared to INCY's ROE of +0.01%. Regarding short-term risk, AKUS is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check INCY's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, UTHR has a market cap of 13.4B. Regarding current trading prices, AKUS is priced at $13.29, while UTHR trades at $298.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas UTHR's P/E ratio is 11.88. In terms of profitability, AKUS's ROE is -0.32%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, AKUS is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check UTHR's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, MRNA has a market cap of 13.1B. Regarding current trading prices, AKUS is priced at $13.29, while MRNA trades at $33.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas MRNA's P/E ratio is -3.88. In terms of profitability, AKUS's ROE is -0.32%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, AKUS is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check MRNA's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, AKUS is priced at $13.29, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas KRTX's P/E ratio is -28.09. In terms of profitability, AKUS's ROE is -0.32%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, AKUS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check KRTX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, EXEL has a market cap of 12.1B. Regarding current trading prices, AKUS is priced at $13.29, while EXEL trades at $44.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas EXEL's P/E ratio is 20.27. In terms of profitability, AKUS's ROE is -0.32%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, AKUS is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check EXEL's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, AKUS is priced at $13.29, while BMRN trades at $58.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas BMRN's P/E ratio is 21.53. In terms of profitability, AKUS's ROE is -0.32%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, AKUS is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check BMRN's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ASND has a market cap of 9.9B. Regarding current trading prices, AKUS is priced at $13.29, while ASND trades at $164.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ASND's P/E ratio is -24.04. In terms of profitability, AKUS's ROE is -0.32%, compared to ASND's ROE of +1.91%. Regarding short-term risk, AKUS is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check ASND's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, AKUS is priced at $13.29, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas RXDX's P/E ratio is -56.47. In terms of profitability, AKUS's ROE is -0.32%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, AKUS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check RXDX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, AKUS is priced at $13.29, while TECH trades at $58.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas TECH's P/E ratio is 70.54. In terms of profitability, AKUS's ROE is -0.32%, compared to TECH's ROE of +0.06%. Regarding short-term risk, AKUS is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check TECH's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, AKUS is priced at $13.29, while VRNA trades at $105.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas VRNA's P/E ratio is -52.54. In terms of profitability, AKUS's ROE is -0.32%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, AKUS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check VRNA's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, BBIO has a market cap of 8.8B. Regarding current trading prices, AKUS is priced at $13.29, while BBIO trades at $46.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas BBIO's P/E ratio is -12.99. In terms of profitability, AKUS's ROE is -0.32%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, AKUS is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check BBIO's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, AKUS is priced at $13.29, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas IMGN's P/E ratio is -111.55. In terms of profitability, AKUS's ROE is -0.32%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, AKUS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check IMGN's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, AKUS is priced at $13.29, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas BPMC's P/E ratio is -51.58. In terms of profitability, AKUS's ROE is -0.32%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, AKUS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check BPMC's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, AKUS is priced at $13.29, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas CERE's P/E ratio is -16.47. In terms of profitability, AKUS's ROE is -0.32%, compared to CERE's ROE of -0.43%. Regarding short-term risk, AKUS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check CERE's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, AKUS is priced at $13.29, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, AKUS's ROE is -0.32%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, AKUS is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check ROIVW's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, AKUS is priced at $13.29, while ROIV trades at $11.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ROIV's P/E ratio is -15.13. In terms of profitability, AKUS's ROE is -0.32%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, AKUS is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check ROIV's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, CORT has a market cap of 7.3B. Regarding current trading prices, AKUS is priced at $13.29, while CORT trades at $69.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas CORT's P/E ratio is 60.13. In terms of profitability, AKUS's ROE is -0.32%, compared to CORT's ROE of +0.20%. Regarding short-term risk, AKUS is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check CORT's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, HALO has a market cap of 7.1B. Regarding current trading prices, AKUS is priced at $13.29, while HALO trades at $57.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas HALO's P/E ratio is 15.35. In terms of profitability, AKUS's ROE is -0.32%, compared to HALO's ROE of +1.22%. Regarding short-term risk, AKUS is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check HALO's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, JAZZ has a market cap of 7.1B. Regarding current trading prices, AKUS is priced at $13.29, while JAZZ trades at $117.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas JAZZ's P/E ratio is 15.93. In terms of profitability, AKUS's ROE is -0.32%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, AKUS is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check JAZZ's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, AKUS is priced at $13.29, while RVMD trades at $37.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas RVMD's P/E ratio is -9.29. In terms of profitability, AKUS's ROE is -0.32%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, AKUS is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check RVMD's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, AKUS is priced at $13.29, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas RETA's P/E ratio is -66.29. In terms of profitability, AKUS's ROE is -0.32%, compared to RETA's ROE of +0.47%. Regarding short-term risk, AKUS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check RETA's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, IONS has a market cap of 6.6B. Regarding current trading prices, AKUS is priced at $13.29, while IONS trades at $41.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas IONS's P/E ratio is -13.77. In terms of profitability, AKUS's ROE is -0.32%, compared to IONS's ROE of -0.92%. Regarding short-term risk, AKUS is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check IONS's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, MDGL has a market cap of 6.5B. Regarding current trading prices, AKUS is priced at $13.29, while MDGL trades at $294.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas MDGL's P/E ratio is -16.49. In terms of profitability, AKUS's ROE is -0.32%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, AKUS is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check MDGL's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, AMRN has a market cap of 6.2B. Regarding current trading prices, AKUS is priced at $13.29, while AMRN trades at $14.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas AMRN's P/E ratio is -3.41. In terms of profitability, AKUS's ROE is -0.32%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, AKUS is less volatile compared to AMRN. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check AMRN's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, NUVL has a market cap of 5.9B. Regarding current trading prices, AKUS is priced at $13.29, while NUVL trades at $81.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas NUVL's P/E ratio is -18.55. In terms of profitability, AKUS's ROE is -0.32%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, AKUS is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check NUVL's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, TGTX has a market cap of 5.7B. Regarding current trading prices, AKUS is priced at $13.29, while TGTX trades at $35.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas TGTX's P/E ratio is 143.96. In terms of profitability, AKUS's ROE is -0.32%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, AKUS is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check TGTX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, RYTM has a market cap of 5.6B. Regarding current trading prices, AKUS is priced at $13.29, while RYTM trades at $85.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas RYTM's P/E ratio is -30.60. In terms of profitability, AKUS's ROE is -0.32%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, AKUS is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check RYTM's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, AKUS is priced at $13.29, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, AKUS's ROE is -0.32%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, AKUS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check ABCM's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, AKUS is priced at $13.29, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ISEE's P/E ratio is -22.44. In terms of profitability, AKUS's ROE is -0.32%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, AKUS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check ISEE's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, AKUS is priced at $13.29, while CRSP trades at $63.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas CRSP's P/E ratio is -14.20. In terms of profitability, AKUS's ROE is -0.32%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, AKUS is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check CRSP's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, AXSM has a market cap of 4.9B. Regarding current trading prices, AKUS is priced at $13.29, while AXSM trades at $100.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas AXSM's P/E ratio is -17.41. In terms of profitability, AKUS's ROE is -0.32%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, AKUS is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check AXSM's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, MRUS has a market cap of 4.9B. Regarding current trading prices, AKUS is priced at $13.29, while MRUS trades at $65.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas MRUS's P/E ratio is -15.77. In terms of profitability, AKUS's ROE is -0.32%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, AKUS is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check MRUS's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, TLX has a market cap of 4.7B. Regarding current trading prices, AKUS is priced at $13.29, while TLX trades at $13.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas TLX's P/E ratio is 139.60. In terms of profitability, AKUS's ROE is -0.32%, compared to TLX's ROE of +0.06%. Regarding short-term risk, AKUS is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check TLX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, PCVX has a market cap of 4.6B. Regarding current trading prices, AKUS is priced at $13.29, while PCVX trades at $35.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas PCVX's P/E ratio is -8.99. In terms of profitability, AKUS's ROE is -0.32%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, AKUS is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check PCVX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, SLNO has a market cap of 4.5B. Regarding current trading prices, AKUS is priced at $13.29, while SLNO trades at $85.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas SLNO's P/E ratio is -17.99. In terms of profitability, AKUS's ROE is -0.32%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, AKUS is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check SLNO's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, AKUS is priced at $13.29, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ALPN's P/E ratio is -101.52. In terms of profitability, AKUS's ROE is -0.32%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, AKUS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check ALPN's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, KRYS has a market cap of 4.4B. Regarding current trading prices, AKUS is priced at $13.29, while KRYS trades at $152.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas KRYS's P/E ratio is 36.58. In terms of profitability, AKUS's ROE is -0.32%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, AKUS is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check KRYS's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, AKUS is priced at $13.29, while CYTK trades at $36.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas CYTK's P/E ratio is -6.92. In terms of profitability, AKUS's ROE is -0.32%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, AKUS is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check CYTK's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ALKS has a market cap of 4.3B. Regarding current trading prices, AKUS is priced at $13.29, while ALKS trades at $26.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ALKS's P/E ratio is 12.46. In terms of profitability, AKUS's ROE is -0.32%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, AKUS is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check ALKS's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ADMA has a market cap of 4.3B. Regarding current trading prices, AKUS is priced at $13.29, while ADMA trades at $18.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ADMA's P/E ratio is 21.43. In terms of profitability, AKUS's ROE is -0.32%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, AKUS is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check ADMA's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ZLAB has a market cap of 4.3B. Regarding current trading prices, AKUS is priced at $13.29, while ZLAB trades at $38.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ZLAB's P/E ratio is -15.48. In terms of profitability, AKUS's ROE is -0.32%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, AKUS is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check ZLAB's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ABVX has a market cap of 4.2B. Regarding current trading prices, AKUS is priced at $13.29, while ABVX trades at $66.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ABVX's P/E ratio is -19.18. In terms of profitability, AKUS's ROE is -0.32%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, AKUS is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check ABVX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, AKUS is priced at $13.29, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas OPT's P/E ratio is -1.52. In terms of profitability, AKUS's ROE is -0.32%, compared to OPT's ROE of +2.60%. Regarding short-term risk, AKUS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check OPT's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, RNA has a market cap of 4.2B. Regarding current trading prices, AKUS is priced at $13.29, while RNA trades at $34.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas RNA's P/E ratio is -11.52. In terms of profitability, AKUS's ROE is -0.32%, compared to RNA's ROE of -0.27%. Regarding short-term risk, AKUS is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check RNA's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, MTSR has a market cap of 4.1B. Regarding current trading prices, AKUS is priced at $13.29, while MTSR trades at $39.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas MTSR's P/E ratio is -15.58. In terms of profitability, AKUS's ROE is -0.32%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, AKUS is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check MTSR's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, AKUS is priced at $13.29, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas MRTX's P/E ratio is -4.82. In terms of profitability, AKUS's ROE is -0.32%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, AKUS is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check MRTX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, AKUS is priced at $13.29, while AKRO trades at $49.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas AKRO's P/E ratio is -13.13. In terms of profitability, AKUS's ROE is -0.32%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, AKUS is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check AKRO's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, AKUS is priced at $13.29, while ACLX trades at $70.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ACLX's P/E ratio is -23.61. In terms of profitability, AKUS's ROE is -0.32%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, AKUS is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check ACLX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, LEGN has a market cap of 3.8B. Regarding current trading prices, AKUS is priced at $13.29, while LEGN trades at $41.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas LEGN's P/E ratio is -35.18. In terms of profitability, AKUS's ROE is -0.32%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, AKUS is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check LEGN's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, AKUS is priced at $13.29, while ACAD trades at $22.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ACAD's P/E ratio is 16.51. In terms of profitability, AKUS's ROE is -0.32%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, AKUS is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check ACAD's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, AKUS is priced at $13.29, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas RYZB's P/E ratio is -57.86. In terms of profitability, AKUS's ROE is -0.32%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, AKUS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check RYZB's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, AKUS is priced at $13.29, while VKTX trades at $33.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas VKTX's P/E ratio is -21.56. In terms of profitability, AKUS's ROE is -0.32%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, AKUS is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check VKTX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, AKUS is priced at $13.29, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas CBAY's P/E ratio is -32.81. In terms of profitability, AKUS's ROE is -0.32%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, AKUS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check CBAY's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, AAPG has a market cap of 3.6B. Regarding current trading prices, AKUS is priced at $13.29, while AAPG trades at $39.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas AAPG's P/E ratio is -52.39. In terms of profitability, AKUS's ROE is -0.32%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, AKUS is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check AAPG's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, AKUS is priced at $13.29, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas SWTX's P/E ratio is -13.78. In terms of profitability, AKUS's ROE is -0.32%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, AKUS is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check SWTX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, SRRK has a market cap of 3.5B. Regarding current trading prices, AKUS is priced at $13.29, while SRRK trades at $37.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas SRRK's P/E ratio is -14.55. In terms of profitability, AKUS's ROE is -0.32%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, AKUS is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check SRRK's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, PTCT has a market cap of 3.5B. Regarding current trading prices, AKUS is priced at $13.29, while PTCT trades at $44.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas PTCT's P/E ratio is 6.81. In terms of profitability, AKUS's ROE is -0.32%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, AKUS is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check PTCT's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, AKUS is priced at $13.29, while PTGX trades at $56.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas PTGX's P/E ratio is 72.14. In terms of profitability, AKUS's ROE is -0.32%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, AKUS is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check PTGX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, AKUS is priced at $13.29, while MLTX trades at $54.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas MLTX's P/E ratio is -23.68. In terms of profitability, AKUS's ROE is -0.32%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, AKUS is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check MLTX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, KYMR has a market cap of 3.1B. Regarding current trading prices, AKUS is priced at $13.29, while KYMR trades at $44.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas KYMR's P/E ratio is -14.21. In terms of profitability, AKUS's ROE is -0.32%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, AKUS is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check KYMR's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, IMVT has a market cap of 2.9B. Regarding current trading prices, AKUS is priced at $13.29, while IMVT trades at $16.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas IMVT's P/E ratio is -6.14. In terms of profitability, AKUS's ROE is -0.32%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, AKUS is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check IMVT's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, AKUS is priced at $13.29, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas MORF's P/E ratio is -14.88. In terms of profitability, AKUS's ROE is -0.32%, compared to MORF's ROE of -0.22%. Regarding short-term risk, AKUS is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check MORF's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, AKUS is priced at $13.29, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas MOR's P/E ratio is -12.64. In terms of profitability, AKUS's ROE is -0.32%, compared to MOR's ROE of -1.84%. Regarding short-term risk, AKUS is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check MOR's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, AKUS is priced at $13.29, while CRNX trades at $30.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas CRNX's P/E ratio is -7.97. In terms of profitability, AKUS's ROE is -0.32%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, AKUS is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check CRNX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, NAMSW has a market cap of 2.7B. Regarding current trading prices, AKUS is priced at $13.29, while NAMSW trades at $12.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas NAMSW's P/E ratio is N/A. In terms of profitability, AKUS's ROE is -0.32%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, AKUS is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check NAMSW's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, AKUS is priced at $13.29, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas KDNY's P/E ratio is -12.47. In terms of profitability, AKUS's ROE is -0.32%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, AKUS is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check KDNY's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, RXRX has a market cap of 2.7B. Regarding current trading prices, AKUS is priced at $13.29, while RXRX trades at $6.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas RXRX's P/E ratio is -3.51. In terms of profitability, AKUS's ROE is -0.32%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, AKUS is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check RXRX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, NAMS has a market cap of 2.6B. Regarding current trading prices, AKUS is priced at $13.29, while NAMS trades at $23.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas NAMS's P/E ratio is -12.73. In terms of profitability, AKUS's ROE is -0.32%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, AKUS is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check NAMS's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, AKUS is priced at $13.29, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas MYOV's P/E ratio is -14.05. In terms of profitability, AKUS's ROE is -0.32%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, AKUS is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check MYOV's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, RARE has a market cap of 2.6B. Regarding current trading prices, AKUS is priced at $13.29, while RARE trades at $27.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas RARE's P/E ratio is -4.74. In terms of profitability, AKUS's ROE is -0.32%, compared to RARE's ROE of -1.86%. Regarding short-term risk, AKUS is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check RARE's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, AKUS is priced at $13.29, while LGND trades at $134.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas LGND's P/E ratio is -18.51. In terms of profitability, AKUS's ROE is -0.32%, compared to LGND's ROE of -0.16%. Regarding short-term risk, AKUS is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check LGND's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, AKUS is priced at $13.29, while MIRM trades at $51.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas MIRM's P/E ratio is -31.98. In terms of profitability, AKUS's ROE is -0.32%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, AKUS is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check MIRM's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, AKUS is priced at $13.29, while CPRX trades at $20.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas CPRX's P/E ratio is 13.25. In terms of profitability, AKUS's ROE is -0.32%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, AKUS is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check CPRX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, XENE has a market cap of 2.4B. Regarding current trading prices, AKUS is priced at $13.29, while XENE trades at $30.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas XENE's P/E ratio is -9.62. In terms of profitability, AKUS's ROE is -0.32%, compared to XENE's ROE of -0.32%. Regarding short-term risk, AKUS is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check XENE's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, AKUS is priced at $13.29, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas PRVB's P/E ratio is -16.43. In terms of profitability, AKUS's ROE is -0.32%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, AKUS is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check PRVB's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, APGE has a market cap of 2.4B. Regarding current trading prices, AKUS is priced at $13.29, while APGE trades at $39.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas APGE's P/E ratio is -10.99. In terms of profitability, AKUS's ROE is -0.32%, compared to APGE's ROE of -0.19%. Regarding short-term risk, AKUS is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check APGE's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, APLS has a market cap of 2.4B. Regarding current trading prices, AKUS is priced at $13.29, while APLS trades at $18.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas APLS's P/E ratio is -10.41. In terms of profitability, AKUS's ROE is -0.32%, compared to APLS's ROE of -1.00%. Regarding short-term risk, AKUS is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check APLS's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, AKUS is priced at $13.29, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas LBPH's P/E ratio is -26.66. In terms of profitability, AKUS's ROE is -0.32%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, AKUS is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check LBPH's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, IBRX has a market cap of 2.3B. Regarding current trading prices, AKUS is priced at $13.29, while IBRX trades at $2.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas IBRX's P/E ratio is -4.65. In terms of profitability, AKUS's ROE is -0.32%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, AKUS is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check IBRX's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, AKUS is priced at $13.29, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas DICE's P/E ratio is -21.91. In terms of profitability, AKUS's ROE is -0.32%, compared to DICE's ROE of +0.56%. Regarding short-term risk, AKUS is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for AKUS.Check DICE's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, AKUS is priced at $13.29, while ARWR trades at $16.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas ARWR's P/E ratio is -13.06. In terms of profitability, AKUS's ROE is -0.32%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, AKUS is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check ARWR's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, AKUS is priced at $13.29, while IDYA trades at $25.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas IDYA's P/E ratio is -6.85. In terms of profitability, AKUS's ROE is -0.32%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, AKUS is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check IDYA's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, AKUS is priced at $13.29, while GLPG trades at $32.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas GLPG's P/E ratio is -6.35. In terms of profitability, AKUS's ROE is -0.32%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, AKUS is less volatile compared to GLPG. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check GLPG's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, AKUS is priced at $13.29, while AGIO trades at $37.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas AGIO's P/E ratio is 3.22. In terms of profitability, AKUS's ROE is -0.32%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, AKUS is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check AGIO's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, AKUS is priced at $13.29, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas CALT's P/E ratio is -22.73. In terms of profitability, AKUS's ROE is -0.32%, compared to CALT's ROE of -1.67%. Regarding short-term risk, AKUS is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check CALT's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, IMRA has a market cap of 2.1B. Regarding current trading prices, AKUS is priced at $13.29, while IMRA trades at $42.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas IMRA's P/E ratio is N/A. In terms of profitability, AKUS's ROE is -0.32%, compared to IMRA's ROE of -0.41%. Regarding short-term risk, AKUS is less volatile compared to IMRA. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check IMRA's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, BEAM has a market cap of 2.1B. Regarding current trading prices, AKUS is priced at $13.29, while BEAM trades at $20.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas BEAM's P/E ratio is -4.52. In terms of profitability, AKUS's ROE is -0.32%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, AKUS is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check BEAM's competition here

AKUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKUS stands at 0. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, AKUS is priced at $13.29, while VCEL trades at $41.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKUS currently has a P/E ratio of -4.69, whereas VCEL's P/E ratio is 829.00. In terms of profitability, AKUS's ROE is -0.32%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, AKUS is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for AKUS.Check VCEL's competition here